Introduction: There is continued unmet medical need for new medicines across countries
especially for cancer, immunological diseases, and orphan diseases. However, there are …

Medicines have made an appreciable contribution to improving health. However, even high-
income countries are struggling to fund new premium-priced medicines. This will grow …

Introduction: The appreciable growth in pharmaceutical expenditure has resulted in multiple
initiatives across Europe to lower generic prices and enhance their utilization. However …

In 2019, the Chinese government implemented the first round of the National Centralized
Drug Procurement (NCDP) pilot (so-called “4+ 7” policy) in mainland China, in which 25 …

Introduction: There is an urgent need for health authorities across Europe to fully realize
potential savings from increased use of generics to sustain their healthcare systems. A …

Medicines receiving a conditional marketing authorization through Medicines Adaptive
Pathways to Patients (MAPPs) will be a challenge for payers. The “introduction” of MAPPs is …

ABSTRACT Introduction: The WHO identified Pharmacy and Therapeutics Committees
(PTCs) as a pivotal model to promote rational medicine use in hospitals. This matches a key …

The potential benefits of early patient access to new medicines in areas of high unmet
medical need are recognised, but uncertainties concerning effectiveness, safety and added …

Background: There are potential conflicts between authorities and companies to fund new
premium priced drugs especially where there are effectiveness, safety and/or budget …

Quality indicators are increasingly used as a tool to achieve safe and quality clinical care,
cost‐effective therapy, for professional learning, remuneration, accreditation and financial …